Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Renal Cell Carcinoma

Journal Scan / Research · October 26, 2022

Real-World Comparative Effectiveness of First-Line Ipilimumab and Nivolumab vs Axitinib and Pembrolizumab in mRCC

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
Oncologist 2022 Oct 06;[EPub Ahead of Print], KK Zarrabi, E Handorf, B Miron, MR Zibelman, F Anari, P Ghatalia, ER Plimack, DM Geynisman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading